Medexus Pharmaceuticals (TSE:MDP) Downgraded to Hold Rating by Stifel Canada

Medexus Pharmaceuticals (TSE:MDP - Get Free Report) was downgraded by Stifel Canada from a "strong-buy" rating to a "hold" rating in a research note issued on Thursday,Zacks.com reports.

A number of other research analysts have also recently issued reports on the company. Leede Financial raised Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, January 22nd. Ventum Financial raised their price objective on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a "buy" rating in a research report on Thursday, January 30th. Stifel Nicolaus cut shares of Medexus Pharmaceuticals from a "buy" rating to a "hold" rating and lowered their price objective for the company from C$6.00 to C$3.45 in a research report on Friday, February 7th. Raymond James upgraded shares of Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 price objective for the company in a research report on Wednesday, January 8th. Finally, Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a "strong-buy" rating in a research report on Monday, December 23rd. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of C$5.49.

Medexus Pharmaceuticals Stock Performance

Shares of TSE:MDP traded down C$0.13 during trading on Thursday, hitting C$3.12. 80,591 shares of the stock were exchanged, compared to its average volume of 189,203. The company's fifty day simple moving average is C$3.56 and its 200-day simple moving average is C$2.85. The company has a market capitalization of C$76.53 million, a price-to-earnings ratio of 62.40 and a beta of 1.96. Medexus Pharmaceuticals has a 1-year low of C$1.47 and a 1-year high of C$5.56.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.